Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NASD]
Sanofi
Index- P/E9.88 EPS (ttm)5.24 Insider Own16.40% Shs Outstand2.50B Perf Week-0.08%
Market Cap129.78B Forward P/E13.77 EPS next Y3.76 Insider Trans0.00% Shs Float2.24B Perf Month-0.79%
Income13.19B PEG1.14 EPS next Q1.11 Inst Own7.60% Short Float0.16% Perf Quarter5.56%
Sales44.65B P/S2.91 EPS this Y-32.80% Inst Trans-0.24% Short Ratio2.61 Perf Half Y6.48%
Book/sh29.96 P/B1.73 EPS next Y10.17% ROA- Target Price58.38 Perf Year28.38%
Cash/sh7.55 P/C6.86 EPS next 5Y8.70% ROE- 52W Range37.62 - 55.00 Perf YTD3.17%
Dividend1.70 P/FCF- EPS past 5Y-6.40% ROI3.50% 52W High-6.11% Beta0.59
Dividend %3.28% Quick Ratio1.40 Sales past 5Y3.30% Gross Margin67.80% 52W Low37.27% ATR1.10
Employees100409 Current Ratio1.90 Sales Q/Q0.30% Oper. Margin- RSI (14)47.61 Volatility1.65% 1.72%
OptionableYes Debt/Eq0.39 EPS Q/Q781.40% Profit Margin- Rel Volume0.92 Prev Close51.79
ShortableYes LT Debt/Eq0.34 EarningsJul 29 BMO Payout- Avg Volume1.36M Price51.64
Recom1.40 SMA20-1.20% SMA500.67% SMA2006.57% Volume987,726 Change-0.29%
Mar-17-20Upgrade Barclays Underweight → Equal Weight
Mar-11-20Upgrade Goldman Neutral → Buy
Feb-11-20Initiated SVB Leerink Mkt Perform
Jan-06-20Upgrade JP Morgan Neutral → Overweight
Sep-23-19Upgrade Guggenheim Neutral → Buy
Sep-20-19Upgrade Morgan Stanley Equal-Weight → Overweight
Sep-03-19Initiated Bernstein Outperform
Aug-14-19Upgrade UBS Neutral → Buy
Dec-11-18Upgrade Jefferies Hold → Buy
Nov-01-18Upgrade Barclays Underweight → Equal Weight
Oct-09-18Initiated Guggenheim Neutral
Sep-10-18Upgrade BofA/Merrill Neutral → Buy
Aug-10-18Upgrade Citigroup Neutral → Buy
Mar-23-18Upgrade Liberum Hold → Buy
Jan-23-18Downgrade Barclays Equal Weight → Underweight
Dec-06-17Downgrade BofA/Merrill Buy → Neutral
Dec-01-17Downgrade Morgan Stanley Overweight → Underweight
Nov-15-17Upgrade Barclays Underweight → Equal Weight
Aug-30-17Upgrade HSBC Securities Reduce → Hold
May-11-17Downgrade Berenberg Buy → Hold
Aug-05-20 12:55PM  
11:43AM  
11:27AM  
10:20AM  
10:06AM  
Aug-04-20 05:23PM  
09:21AM  
06:30AM  
Aug-03-20 06:09AM  
04:23AM  
Aug-02-20 07:39AM  
06:39AM  
Aug-01-20 06:49AM  
06:33AM  
Jul-31-20 11:56PM  
06:42PM  
04:55PM  
04:35PM  
03:51PM  
03:20PM  
01:05PM  
12:44PM  
12:19PM  
11:47AM  
10:36AM  
09:25AM  
07:47AM  
07:45AM  
07:33AM  
07:25AM  
07:18AM  
07:07AM  
07:00AM  
07:00AM  
07:00AM  
Jul-30-20 03:01PM  
11:02AM  
02:15AM  
Jul-29-20 02:52PM  
11:29AM  
11:03AM  
10:55AM  
10:38AM  
09:08AM  
08:00AM  
07:32AM  
07:24AM  
05:23AM  
04:30AM  
02:28AM  
01:53AM  
01:30AM  
01:14AM  
01:02AM  
01:00AM  
Jul-28-20 06:24PM  
Jul-27-20 06:07PM  
12:10PM  
11:20AM  
11:16AM  
Jul-24-20 07:01PM  
04:57PM  
12:16PM  
Jul-23-20 12:45PM  
Jul-21-20 12:19PM  
11:45AM  
Jul-20-20 07:26AM  
Jul-19-20 11:11AM  
08:37AM  
Jul-17-20 05:23PM  
07:59AM  
07:36AM  
07:29AM  
04:13AM  
02:24AM  
Jul-16-20 03:52PM  
11:29AM  
09:22AM  
Jul-14-20 07:00AM  
Jul-13-20 06:33PM  
Jul-10-20 07:43AM  
Jul-09-20 09:41AM  
08:40AM  
07:00AM  
Jul-08-20 11:30AM  
Jul-07-20 07:03AM  
Jul-06-20 04:42PM  
03:39PM  
01:25PM  
08:24AM  
07:26AM  
Jul-05-20 02:51AM  
02:33AM  
Jul-03-20 08:22AM  
08:19AM  
Jul-02-20 10:15PM  
04:59PM  
04:44PM  
Jul-01-20 09:46AM  
07:00AM  
Sanofi provides therapeutic solutions worldwide. It offers Cerezyme and Cerdelga for Gaucher, Myozyme and Lumizyme for Pompe, Fabrazyme for Fabry, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio and Lemtrada for multiple sclerosis. It also provides Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Eloctate and Alprolix to treat hemophilia; and Cablivi to treat acquired thrombotic thrombocytopenic purpura. In addition, it offers Libtayo for metastatic cutaneous squamous cell carcinoma; Jevtana and Taxotere taxane for cancers; Eloxatin for colon cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil for hematologic malignancies; and Zaltrap for metastatic colorectal cancer. Further, it provides Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl sulfonylurea; Adlyxin/Lyxumia, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Additionally, it offers Plavix for atherothrombotic conditions; Lovenox for the prophylaxis, venous thromboembolism, and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; Allegra for seasonal allergic rhinitis and uncomplicated hives; and Depakine for epilepsy. It also provides generic products; and products for allergy, cough, cold, pain, nutrition, digestion, pediatrics, influenza, meningitis, travel, and endemic vaccines; and adult and adolescent boosters. Sanofi has collaborations with Verily Life Sciences LLC; Happify Health; GlaxoSmithKline Plc; and Kymera Therapeutics. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJul 28Buy16.0081,2501,300,000520,125Jul 29 06:06 AM
Sanofi10% OwnerJun 09Sale597.48120,23471,837,410279,766Jun 11 06:45 PM
Sanofi10% OwnerMay 29Sale509.852,399,5521,223,411,587400,000May 29 04:16 PM
Sanofi10% OwnerMay 29Sale509.8520,421,89910,412,105,2050May 29 04:16 PM
Sanofi10% OwnerMar 09Sale489.65128,91463,123,15320,421,899Mar 11 05:00 PM
Sanofi10% OwnerSep 10Sale281.15172,90448,611,80420,550,813Sep 12 05:00 PM